Enveric Biosciences Announces $13.9 Million Private Placement

Biotech firm secures funding for neurological drug development

Apr. 17, 2026 at 4:56am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, industrial-looking financial machinery and equipment, conveying a sense of power, security, and institutional wealth without using literal currency or charts.This private placement financing will provide critical capital to support Enveric's efforts to advance its pipeline of innovative neurological drug candidates.Cambridge Today

Enveric Biosciences, a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics, announced a $13.9 million private placement. The deal includes $5 million in upfront funding, with an additional $8.9 million in potential proceeds from the exercise of warrants.

Why it matters

This financing will provide critical capital to support Enveric's efforts to advance its pipeline of novel compounds designed to address unmet needs in psychiatric and neurological disorders. As the company works to develop new treatments, this funding represents an important milestone in its growth.

The details

The private placement includes the sale of 2,222,223 shares of Enveric's common stock (or pre-funded warrants) at $2.25 per share, along with Series I warrants exercisable at $2 per share and short-term Series J warrants. H.C. Wainwright & Co. acted as the exclusive placement agent. Enveric plans to use the net proceeds for product development, working capital, and general corporate purposes.

  • The private placement is expected to close on or about April 17, 2026.

The players

Enveric Biosciences

A biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics to address unmet needs in psychiatric and neurological disorders.

H.C. Wainwright & Co.

The exclusive placement agent for Enveric's private placement.

Got photos? Submit your photos here. ›

What’s next

The company intends to use the net proceeds from the offering for product development, working capital, and general corporate purposes.

The takeaway

This private placement represents an important milestone for Enveric as it works to develop new treatments for psychiatric and neurological disorders, providing the necessary funding to advance its pipeline of innovative neuroplastogenic therapeutics.